|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Analysis of potential predictive markers of cetuximab benefit in BMS099,a phase Ⅲ study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer显示文摘 | Khambata-Ford S Harbison CT Hart LL | | 0，，06： | 1 |
| 2 | Genome - wide map of nucleosome acetylation and methylation in yeast 显示文摘 | Pokholok DK Harbison CT Levine S | 2005 | Cell2005，122，： | 1 |
| 3 | Analysis of potential predictive markers of cetuximab benefit in BMS099,a phase Ⅲ study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer显示文摘 | Khambata-Ford S Harbison CT Hart LL | 2010 | J Clin Oncol2010，28，6： | 1 |
| 4 | K-Ras mutations (MT) and EGFR-related markers as potential predictors of cetuximab benefit in 1 st line advanced NSCLC:Results from the BMS099 study显示文摘 | Khambata-Ford S Harbison CT Hart LL | 2008 | J Thorac Oncol2008，，： | 1 |
| 5 | Analysis of potential predictive markers of cetuximab benefit in BMS099,a phase Ⅲ study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer显示文摘 | Khambata-Ford S Harbison CT Hart LL | 2010 | J Clin Oncol2010，28，6： | 1 |
| 6 | Genome-wide map of nucleosome acetylation and methylation in yeast显示文摘 | Pokholok DK Harbison CT Levine S | 2005 | Cell2005，122，4： | 1 |
| 7 | Genome-wide map of nncleosome acetylation and methylation in yeast 显示文摘 | Pokholok DK Harbison CT Levine S | 2005 | Cell2005，122，4： | 1 |
| 8 | Transcriptional regulato- ry code of a eukaryotic genome显示文摘 | HARBISON CT GORDON DB LEE TI | 2004 | Nature2004，431，7004： | 1 |
| 9 | Analysis of po- tential predictive markers of Cetuximab benefit in BMS099, a phase Ⅱ study of Cetuximab and first-line Taxane/Carboplatin in advanced non-small-cell lung cancer显示文摘 | Khambata-Ford S Harbison CT Hart LL | 2010 | J Clin Oncol2010，28，6： | 1 |
| 10 | Transcriptional regulatory code of a eukaryotic genome显示文摘 | Harbison CT Gordon DB Lee TI | 2004 | Nature2004，431，7004： | 1 |
| 11 | Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first - line tax- ane/carboplatin in advanced non - small - cell lung cancer 显示文摘 | Khambata - Ford S Harbison CT Hart LL | 2010 | J Clin Oncol2010，28，6： | 1 |
| 12 | Analysis of potential predictive markers of cetuximab benefit inBMS099, a phase Ⅲ study of cetuximab and first-line taxane/carbo- platin in advanced non-small-cell lung cancer显示文摘 | Khambata-Ford S Harbison CT Hart LL | 2010 | J Clin Oncol2010，28，6： | 1 |
| 13 | Analysis of potential predictive markers of cetuximab benefit in BMS099,a phaseⅢstudy of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer显示文摘 | Khambata-Ford S Harbison CT Hart LL | 2010 | J Clin Oncol2010，28，6： | 1 |
| 14 | Analysis of poten- tial predictive markers of cetuximab benefit in BMS099, a phase Ⅲ study of cetuximab and first - line taxane/carboplatin in advanced non -small-cell lung cancer显示文摘 | Khambata- Ford S Harbison CT Hart LL | 2010 | J Clin Oncol2010，28，6： | 1 |
| 15 | Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase Ⅲ study of cetuximab and first-line taxane/carbopla- tin in advanced non-small-cell lung cancer 显示文摘 | Khambata Ford S Harbison CT Hart LL | 2010 | J Clin On- col2010，28，6： | 1 |
| 16 | BMS099试验:西妥昔单抗疗效预测标志物分析显示文摘西妥昔单抗。一种表皮生长因子受体(EGFR)抗体,已被证实对多种类型的肿瘤有效。但若能根据预测该药疗效的标志物筛选目标患者,治疗成功率就能增加。BMS099Ⅲ期临床试验对此进行了探讨。选择西妥昔单抗治疗中晚期非小细胞癌(NSCLC),寻找预测该药疗效的分子标志物。 | Khambata-Ford S Harbison CT Hart LL | 2010 | 中国处方药2010，，3： | 1 |
| 17 | Programspecific distribution of a transcription factor dependent on partner transcription factor and MAPK signaling显示文摘 | Zeitlinger J Simon I Harbison CT | 2003 | Cell2003，113，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员